<DOC>
	<DOC>NCT00413686</DOC>
	<brief_summary>This is an open-label, multi-center, dose-escalation, Phase I study to evaluate the safety, tolerability, and pharmacokinetics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with gemcitabine. The study is sponsored by AstraZeneca.</brief_summary>
	<brief_title>Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective ECOG performance status of 0 or 1 Patient and tumor type must be suitable for treatment with weekly standard gemcitabine. Inadequate bone marrow reserve, inadequate liver function or impaired renal function Any troponin elevation (above normal range) Stage II, III, or IV cardiac status, according to New York Heart Association (NYHA) classification; recent history (ie, within 6 months) of coronary artery disease or arteriosclerotic cardiovascular disease (angina, myocardial infarction [MI]) Any prior anthracycline treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Mixed solid tumors</keyword>
</DOC>